10X Genomics Inc

10X Genomics Inc(TXG)の株式分析

$69.890

+0.028 (+0.04%)終値時点

Loading chart…
高値
72.480
始値
71.480
出来高加重平均価格
70.29
出来高
2.53M
時価総額
2.38B
安値
68.500
売買代金
177.65M
EV/EBITDA(TTM)
-8.95

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

www.10xgenomics.com

バリュエーション指標

10X Genomics Inc(TXG)の現在の予想PERは-9.54で、5年平均は-47.51です。

予想PER

適正
5年平均 P/E
-47.51
現在のP/E
-9.54
割高
40.77
割安
-135.78

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-469.07
現在のEV/EBITDA
-8.95
割高
1350.44
割安
-2288.58

予想PSR

適正
5年平均 P/S
8.51
現在のP/S
2.27
割高
14.85
割安
2.17

Alphio AI による TXG の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%TXG

$7.67

シナリオ価格

基

基本

基本 · 50%TXG

$7.57

シナリオ価格

弱

弱気

弱気 · 25%TXG

$6.64

シナリオ価格

TXG を保有するクジラ

H

Harvard Management Company, Inc.

+ を保有TXG

+10.70%

3か月リターン

A

ARK Investment Management LLC

+ を保有TXG

+8.68%

3か月リターン

S

Sprott Inc.

+ を保有TXG

+6.31%

3か月リターン

D

Davy Global Fund Management Limited

+ を保有TXG

+6.11%

3か月リターン

B

Baker Steel Capital Managers LLP

+ を保有TXG

+5.77%

3か月リターン

H

Hillsdale Investment Management Inc.

+ を保有TXG

+5.55%

3か月リターン

イベントタイムライン

2026-10-07 (ET)

09:30:00

10x Genomics Partners with Fred Hutchinson Cancer Center for Multi-Project Research

2026-10-06 (ET)

12:30:00

10x Genomics Shares Drop 13.4% to $84.67

2026-09-29 (ET)

09:30:00

10x Genomics Announces First Commercial Shipments of Atera Platform

2026-09-24 (ET)

12:30:00

10x Genomics Stock Rises 7.6% to $81.33

2026-09-10 (ET)

09:30:00

10x Genomics Integrates Lunit's AI Pathology Platform

ニュース

TXG のよくある質問 — Alphio AI が回答

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める